Tusamitamab, as a therapeutic, is an antibody–drug conjugate (ADC) that combines a humanized monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with a potent cytotoxic payload. Structurally, the antibody component belongs to the human immunoglobulin G1 kappa (IgG1κ) subclass and has a molecular mass of approximately 150 kilodaltons (kDa). It is composed of two identical heavy chains and two identical light chains linked by disulfide bonds in the Y-shaped conformation typical of IgG molecules. The antibody is produced recombinantly in mammalian cell systems, such as Chinese Hamster Ovary (CHO) cells, ensuring proper folding and glycosylation.
The variable regions of the heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) that mediate high-affinity binding to a specific extracellular epitope on CEACAM5, a cell-surface glycoprotein involved in cell adhesion and intercellular signaling. This antigen is largely restricted to certain epithelial lineages, making it an accessible and stable target for molecular binding studies. The antibody’s specific recognition enables selective internalization when bound to CEACAM5 at the cell membrane.
The Fc (fragment crystallizable) region of Tusamitamab provides structural stability and extended half-life via neonatal Fc receptor (FcRn) recycling.
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.
Have a product or application question? Consult our FAQs or contact us.
